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ABSTRACT: Neuroendocrine tumors (NETs) are rare, particularly common in the 
rectum. NETs of the colon (not including the appendix and rectum) are most commonly 
found in the cecum, and hepatic flexure involvement is rather infrequent. The clinical 
presentation of colonic NETs is dependent on the primary site. Many are discovered either 
at the time of screening or during the investigation of abdominal pain or anemia. Here we 
present a challenging case of a hepatic flexure colonic NETS of 26 -year-old male treated 
by laparoscopic right hemicolectomy. 
 





Colonic neuroendocrine tumors (NETs) are 
extremely rare. The incidence of colonic NETs is 
1.0-2.0 per 106 and has remained constant over the 
last five decades1. Langhans first described an 
intestinal carcinoid tumor in 18672. However, 
Lubarsch who described its histologic features 
classified it as carcinoma in 18883. In 2000, the 
World Health Organization (WHO) revised an 
earlier classification of these tumors by Williams 
and Sandler to recognize their growing 
heterogeneity as well as neuroendocrine origin4. 
Most colonic NETs are diagnosed via colonoscopy. 
Correct diagnosis of NETs is as important to treat 
as prognosis. Due to the rarity of colonic NETs, we 
aimed to report the case of 26-year-old male with 




A 26-year-old male patient presented to the 
surgical outpatient department with a chief 
symptom of recurrent pain in the right side of his 
abdomen during the previous year. The patient 
reported weakness, lethargy, anorexia and 
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occasional black stool.” On examination, a lump 
was palpable in the right upper abdominal 
quadrant. His laboratory results showed severe 
microcytic hypochromic anemia with hemoglobin 
5.2gm %. The fecal occult blood test was positive. 
Ultrasonography of the abdomen suggested 
thickening over the hepatic flexure and ascending 
colon with multiple mesenteric lymph nodes. 
Tuberculosis of the GI tract was suspected. We 
performed a colonoscopy after preparation of the 
bowel, and found an ulceroproliferative lesion at 
the hepatic flexure of the colon (Figure 1). 
 
 
Figure 1: An ulceroproliferative lesion at the 
hepatic flexure of the colon 
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The biopsy was suggestive of poorly differentiated 
adenocarcinoma. A computed tomography scan of 
the abdomen showed an asymmetric 
circumferential short segment of non-
homogeneously enhanced wall thickness up to 20 
mm at the hepatic flexure and adjacent ascending 
colon. The thickened wall caused a luminal 
narrowing with adjacent extensive fat stranding, 
which suggested the possibility of a malignant 
mass lesion (Figure 2). 
 
 
Figure 2: A computed tomography scan of the 
abdomen showed an asymmetric circumferential 
short segment of non-homogeneously enhanced 
wall thickness up to 20 mm at the hepatic 
flexure and adjacent ascending colon with 
luminal narrowing. 
 
Carcinoembryonic antigen was normal. A 
laparoscopy-assisted right hemicolectomy was 
performed. Histopathological examination of the 
specimen revealed nuclear hyperchromasia with 
strips of stippled chromatin cells arranged in sheets 
with numerous mitoses (Figure 3). Therefore, 
diagnosis of a neuroendocrine tumor (NET) was 
suspected. Immunohistochemical tests were 
advised to confirm the diagnosis. The tumor was 
assessed to identify histological features suggestive 
of high-frequency microsatellite instability (MSI-
H), which was negative in the index case. 
Immunohistochemical findings were positive for 
Synaptophysin and Chromogranin (Cg) and 
negative for PANCK, which confirmed the 
diagnosis of neuroendocrine tumor. A tumor was 
categorized stage IIA according to TNM staging 
and G2 according to grading by WHO 2010. It was 
well-differentiated small cell neuroendocrine 
tumor. The patient was referred to the oncologist 
for further management. We followed a patient for 
1 year without any recurrence. 
 
 
Figure 3: 40X H and E stain showed nuclear 
hyperchromasia with strips of stippled 





The colon proximal to the rectum most commonly 
gives rise to poorly differentiated small cell 
carcinomas, but there are more commonly large 
cell variants or intermediates between the two 
sizes. 
NETs may be mislabeled as adenocarcinoma, 
which affects management and the understanding 
of the prospects for survival5. The prognosis of a 
NET can be uncertain, partly due to the variability 
of their secretions. Nonfunctional NETs may 
present with pain, bleeding, and obstruction, but 
without hormone secretion, then start producing 
hormones, becoming syndromic6. NETs are 
classified based on their embryonic origin and 
vascular supply (foregut, midgut and hindgut). The 
substance secreted by NETs may vary; even 
metastases may secrete substances different from 
the primary tumor. NETs can also cause 
paraneoplastic syndrome because of the secretion 
of entirely different substances not related to their 
original cell properties7. NETs of the colon are the 
largest tumors and have the poorest prognosis 
among all the gastroenteropancreatic - NETs, as 
they commonly metastasize to the liver. 
Correct diagnosis of NETs is as important to treat 
as to prognosis; treatment options for NETS are 
different from those of poorly differentiated 
adenocarcinoma. Colonic NETs are usually treated 
surgically either local resection or conventional 
surgery. Optimal management requires 
multidisciplinary treatment for which options are 
limited. However, everolimus plus octreotide long-
acting repeatable has shown significant benefits 
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and improved outcomes for patients with advanced 
colorectal neuroendocrine tumors8.  
Most colonic NETs are diagnosed via colonoscopy. 
Computed tomography and magnetic resonance 
imaging are more sensitive and specific for 
improved diagnosis and follow up of 
neuroendocrine tumors (NETs). As in this case, 
histological examination and immunohistochemical 





NETs can arise in different organs. Colonic NETs 
are exceptionally rare especially hepatic flexure of 
the colon. Immunohistochemical tests are necessary 
to differentiate NETs from poorly differentiated 
adenocarcinomas. This differentiation is essential 
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